(Q36090744)

12 August 2017

1 reference

title

Review article: current management of primary sclerosing cholangitis (English)

1 reference

primary sclerosing cholangitis

12 August 2017

ascending cholangitis

0 references

1 reference

Cullen SN

1

1 reference

PubMed ID

15813829

12 August 2017

Chapman RW

series ordinal

2

1 reference

PubMed ID

15813829

12 August 2017

language of work or name

English

0 references

publication date

1 April 2005

1 reference

Alimentary Pharmacology & Therapeutics

12 August 2017

1 reference

12 August 2017

21

1 reference

12 August 2017

8

1 reference

12 August 2017

933-948

1 reference

Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population

12 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Side effects of alpha interferon in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Cytokine-stimulated nitric oxide production inhibits adenylyl cyclase and cAMP-dependent secretion in cholangiocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Ursodeoxycholic acid cytoprotection: dancing with death receptors and survival pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Long-Term Effect of Corticosteroid Treatment in Primary Sclerosing Cholangitis Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Do steroids help jaundice caused by primary sclerosing cholangitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Glucocorticoid receptors are downregulated in hepatic T lymphocytes in rats with experimental cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Therapeutic investigations in primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

An open-label pilot trial of cladibrine (2-cholordeoxyadenosine) in patients with primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

A pilot study of etanercept in the treatment of primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: a case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Surgical biliary drainage in primary sclerosing cholangitis. The role of the Hepp-Couinaud approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Evaluation of the pancreaticobiliary ductal systems by intraductal US.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Clinical role of (18)F-FDG PET for initial staging of patients with extrahepatic bile duct cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Genes and viruses in hepatobiliary neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

21 January 2018

Biliary tract cancers.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

A prognostic model for the outcome of liver transplantation in patients with cholestatic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Liver transplantation for sclerosing cholangitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Cholangiographic features of biliary strictures after liver transplantation for primary sclerosing cholangitis: evidence of recurrent disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Recurrent primary sclerosing cholangitis after orthotopic liver transplantation: is chronic rejection part of the disease process?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Disease recurrence after liver transplantation in Western Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Recurrence of primary sclerosing cholangitis after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Graft Failure From Severe Recurrent Primary Sclerosing Cholangitis Following Orthotopic Liver Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Proliferative activity of rectal mucosa and soluble fecal bile acids in patients with normal colons and in patients with colonic polyps or cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Colonic mucosal proliferation is related to serum deoxycholic acid levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Atrophy and neoplastic transformation of the ileal pouch mucosa in patients with ulcerative colitis and primary sclerosing cholangitis: a case control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Long-term outcome of liver transplantation in patients with PSC: a comparative analysis with PBC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Follow-up after liver transplantation for primary sclerosing cholangitis: effects on survival, quality of life, and colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Bile acids with differing hydrophilic-hydrophobic properties do not influence cytokine production by human monocytes and murine Kupffer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Pretransplant prediction of prognosis after liver transplantation in primary sclerosing cholangitis using a cox regression model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

Combined Therapy with Azathioprine, Prednisolone, and Ursodiol in Patients with Primary Sclerosing Cholangitis: A Case Series

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02407.X

10.1111/J.1365-2036.2005.02407.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15813829